Annual report pursuant to Section 13 and 15(d)

Research and Development Agreements - Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from the Research and Development Agreements (Detail)

v3.22.1
Research and Development Agreements - Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from the Research and Development Agreements (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Assets    
Accounts receivable $ 0 $ 234
Liabilities    
Other current liabilities 2,606 2,211
Other liabilities 1,625 1,490
Total liabilities 126,700 80,537
Takeda Pharmaceuticals Inc    
Assets    
Accounts receivable 0 234
Liabilities    
Other current liabilities 0 5,614
Deferred revenue, current 0 789
Deferred revenue, non-current 0 3,106
Other liabilities 0 6,711
Total liabilities $ 0 $ 16,220